Company Overview - TG Therapeutics (NASDAQ: TGTX) is a commercial stage biotech company focused on Briumvi, a treatment for multiple sclerosis [1] Investment Strategy - The investment approach involves careful analysis of earnings reports to identify potential growth opportunities, with past successes including companies like OPRX, OTRK, FUBO, and PLUG [1]

Financial Performance - TG Therapeutics reported first-quarter earnings per share of 3 cents, a shift from a loss of 7 cents a year ago, but below the consensus of 17 cents [1] - The company reported sales of $120.86 million, up from $63.47 million a year ago, beating the consensus of $118.43 million [1] Product Performance - Briumvi's U.S. net sales reached $119.7 million, demonstrating growing confidence in the treatment and increasing adoption by healthcare providers [2][3] - The company presented five-year data from the ULTIMATE I & II Phase 3 trials, showing that 92% of patients were free from disability progression after five years, with an annualized relapse rate of 0.02 during year 5 [4] - No new safety signals emerged over five years of continuous treatment, with no observed cases of progressive multifocal leukoencephalopathy (PML) [4] Future Guidance - TG Therapeutics raised Briumvi's U.S. net product revenue target to $560 million for fiscal 2025 from $525 million in prior guidance [5] - The total global revenue target was raised to $575 million from prior guidance of $540 million [5] - Briumvi's U.S. net product revenue is expected to be $135 million in the second quarter of 2025 [5] Stock Performance - TGTX stock was down 13.2% at $37.68 on Monday [6]

Core Insights - TG Therapeutics reported a significant increase in revenue and achieved profitability, but the stock price fell sharply due to investor disappointment [1][4][7] Revenue Performance - The company's revenue for the first quarter was nearly $121 million, almost double the $63.5 million from the same period in 2024, driven primarily by Briumvi sales [2][6] - Analysts had a collective revenue estimate of $117 million, indicating that the actual revenue exceeded expectations [4] Profitability - TG Therapeutics posted a net profit of just over $5 million, or $0.03 per share, compared to an almost $11 million loss in the first quarter of 2024 [4] - The consensus estimate for earnings per share was $0.16, suggesting that the actual profit fell short of analyst expectations [4][7] Pipeline Developments - The company is conducting two phase 1 trials for Briumvi: one for subcutaneous use in relapsing MS patients and another for myasthenia gravis [5] - Additionally, TG is developing a CAR T cell therapy, azercabtagene zapreleucel, which is currently in enrollment for a phase 1 trial [5] Guidance Update - TG Therapeutics raised its guidance for domestic Briumvi sales in 2025 to $560 million, up from a previous estimate of $525 million [6] - Overall revenue guidance was also increased to $575 million from $540 million [6]